Skip to content
Review

Mitochondrial ncRNAs: From Pathological Regulation to Targeted Therapy in Cardiovascular Diseases

Jul 2026 · Journal of Cardiovascular Translational Research · Vol 19 · 0 citations · 49 references
Medicine

TL;DR

Gene therapy targeting mecciRNAs and mt-dsRNAs combined with mitochondrial delivery represents a promising strategy for HF treatment.

View source

Similar papers

Review Open access Jul 2026

The central role of mitochondrial pathology in sepsis-induced cardiomyopathy: from molecular mechanisms to clinical translation

This review examines mitochondrial pathology as the central orchestrator of SIC progression and integrates mitochondrial biology, immunometabolism, and translational medicine to identify promising directions for improving patient outcomes.

Linghong Xu, Jun Zhang, Huijing Tong et al. · 0 citations
Review Open access Sep 2026

Oxidative Stress and Mitochondrial Dysfunction: Molecular Interplay, Disease Mechanisms, Biomarkers, and Emerging Therapeutic Strategies: A Comprehensive Review

Oxidative stress and mitochondrial dysfunction were intimately linked processes driving aging and numerous human diseases. Mitochondria generating reactive oxygen species (ROS) during energy metabolism; physiological ROS levels are vital for cell signaling and adaptation. However, excessive ROS damage mitochondrial DNA...

A. Abdulkader, A. M. Hussein · 0 citations
Review Open access Jul 2026

Targeting mitochondria for the treatment of neurodegenerative diseases

This Review summarizes mitochondrial pathological mechanisms in neurodegenerative diseases and discusses emerging mitochondria-targeted therapeutic strategies, highlighting delivery technologies, therapeutic modalities, and translational challenges.

Qian Li, Ming You · 0 citations
Review Open access Sep 2026

Oxidative Stress and Mitochondrial Dysfunction in Chronic Kidney Disease: From Molecular Mechanisms to Biomarkers and Targeted Therapies

This review emphasizes not only mechanistic advances but also conflicting findings, model limitations, and the barriers that currently separate experimental efficacy from clinically meaningful CKD outcomes.

F. De Luca, Dario Troise, Valentina Camporeale et al. · 1 citation
Review Open access Sep 2026

Natural Small Molecules Targeting Mitochondrial Quality Control for the Treatment of Metabolic Diseases: Mechanisms, Novel Formulations, and Translational Perspectives

This review systematically summarizes the mechanisms of MQC dysregulation in metabolic diseases, the evidence supporting natural small-molecule interventions, and strategies for formulation and delivery optimization.

Chong-Yan Zhao, Yuan Gao, Ting Zhou et al. · 0 citations
Review Open access Jul 2026

Mitochondrial dysfunction-driven PANoptosis in doxorubicin-induced cardiotoxicity: mechanistic insights and intervention strategies

Doxorubicin (DOX) is a broad-spectrum anthracycline chemotherapeutic agent, and its clinical application is severely limited by dose-dependent cardiotoxicity (DIC), for which there are currently no effective clinical interventions. Mitochondria are the central organelles regulating myocardial energy metabolism and cell...

Xin-Yu Xue, Xi-Han Liao, Xing Ji et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.